Clinical lymphoma, myeloma & leukemia · 2026
BCR-ABL1 Transcript ≤10% IS an Early Molecular Response Predictor of Treatment-Free Remission Eligibility in Chronic Myeloid Leukemia.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Rasekh Eman O, Sherif Menna M, Ibrahim Nagwa, Ibraheem Dalia, Ghareeb Mohamed, Elfishawi Sally
Аннотация
BACKGROUND: Tyrosine kinase inhibitors (TKIs) have revolutionized chronic myeloid leukemia (CML) treatment. Early assessment of TKI response is crucial, and while deep molecular responses enable treatment discontinuation in selected patients, strict eligibility criteria are needed to prevent relapse. This study aimed to evaluate factors affecting early response to first-line imatinib in CML to help define criteria for safe treatment discontinuation and achieving treatment-free remission (TFR).
PATIENTS AND METHODS: This retrospective cohort study included all adult patients diagnosed with CML who received first-line imatinib therapy between February 2016 and February 2020.
RESULTS: A total of 144 adult patients with CML were included. The median age at diagnosis was 40 years (range: 21-76 years). Early molecular response (EMR), defined as BCR-ABL1 transcript level ≤10% international scale, was achieved in 72 of 116 evaluable patients (62%), and these patients demonstrated significantly superior event-free survival (p = .001), overall survival (p = .003), and failure-free survival (FFS, p < .001) compared with those without EMR. High-risk scores in SOKAL, ELTS, Hasford, and EUTOS systems were associated with EMR failure. Complete hematologic remission at 3 months (p = .001) and achieving BCR-ABL1 log reductions at 3, 6, and 12 months predicted improved FFS. The b3a2 BCR-ABL1 transcript and achieving BCR-ABL1 levels ≤10% at 3 months were both significantly linked to eligibility for treatment discontinuation (p = .04 and p < .0001, respectively).
CONCLUSION: EMR should be considered a strong surrogate marker for identifying treatment failure. Imatinib-treated patients achieving EMR and carrying the b3a2 BCR-ABL1 transcript may be suitable for TFR if closely monitored under strict protocols.
PATIENTS AND METHODS: This retrospective cohort study included all adult patients diagnosed with CML who received first-line imatinib therapy between February 2016 and February 2020.
RESULTS: A total of 144 adult patients with CML were included. The median age at diagnosis was 40 years (range: 21-76 years). Early molecular response (EMR), defined as BCR-ABL1 transcript level ≤10% international scale, was achieved in 72 of 116 evaluable patients (62%), and these patients demonstrated significantly superior event-free survival (p = .001), overall survival (p = .003), and failure-free survival (FFS, p < .001) compared with those without EMR. High-risk scores in SOKAL, ELTS, Hasford, and EUTOS systems were associated with EMR failure. Complete hematologic remission at 3 months (p = .001) and achieving BCR-ABL1 log reductions at 3, 6, and 12 months predicted improved FFS. The b3a2 BCR-ABL1 transcript and achieving BCR-ABL1 levels ≤10% at 3 months were both significantly linked to eligibility for treatment discontinuation (p = .04 and p < .0001, respectively).
CONCLUSION: EMR should be considered a strong surrogate marker for identifying treatment failure. Imatinib-treated patients achieving EMR and carrying the b3a2 BCR-ABL1 transcript may be suitable for TFR if closely monitored under strict protocols.